+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kuwait cohort of the A1chieve study



Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kuwait cohort of the A1chieve study



Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S465-S468



The A1chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents. Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Kuwait. A total of 1185 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (n = 472), insulin detemir (n = 472), insulin aspart (n = 4), basal insulin plus insulin aspart (n = 188) and other insulin combinations (n = 48). At baseline, glycaemic control was poor for both insulin naïve (mean HbA1c: 9.8%) and insulin user (mean HbA1c: 9.4%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA1c (insulin naïve: -2.4%, insulin users: -1.7%). No major hypoglycaemic episodes were observed at 24 weeks. SADR was reported in 0.1% of insulin users. Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052117393

Download citation: RISBibTeXText

PMID: 24404483

DOI: 10.4103/2230-8210.122080


Related references

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kolkata cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S584-S587, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Oman cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S482-S485, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Haryana cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S538-S541, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Yanbu cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S441-S444, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Delhi cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S530-S533, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Yemen cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S458-S460, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Saiss cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S422-S425, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Abu Dhabi cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S477-S481, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Rajasthan cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S526-S529, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Qatar cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S469-S471, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Punjab cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S534-S537, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Mumbai cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S516-S520, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Hyderabad cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S547-S551, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Gujarat cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S521-S525, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Bangalore cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S557-S560, 2014